drug resistance

envie a um amigo share this

Identification of biomarkers associated with acquired resistance to cetuximab in head and neck tumor cells

The epidermal growth factor receptor (EGFR) is a protein leads to the activation of intracellular pathways that act directly on cell function, changes and survival. Cetuximab (CTX) is an anti-EGFR monoclonal antibody approved for the treatment of patients with head and neck squamous cell carcinoma (HNC) and metastatic colorectal cancer (mCRC). The response of patients with mCRC to cetuximab has already been associated with wild-type KRAS, NRAS and BRAF.

Identificação de biomarcadores associados a resistência adquirida ao cetuximabe em células tumorais de cabeça e pescoço

O receptor do fator de crescimento epidérmico (EGFR) é uma proteína cuja ativação leva à sinalização de vias intracelulares que atuam diretamente na proliferação, migração e sobrevivência celular. O cetuximabe (CTX) é um anticorpo monoclonal anti-EGFR aprovado para o tratamento de pacientes com carcinoma espinocelular de cabeça e pescoço (CECP) e cancro colorectal metastático (mCRC). A resposta de pacientes com mCRC ao cetuximabe já foi associada a forma selvagem de KRAS, NRAS e BRAF.

Harmine and Piperlongumine Revert TRIB2-Mediated Drug Resistance

Poor survival and treatment failure of patients with cancer are mainly due to therapy resistance. Tribbles homologue 2 (TRIB2) has recently been identified as a protein that promotes resistance to several anti-cancer drugs. In this study, RNA sequencing and bioinformatics analysis were used to characterise the impact of TRIB2 on the expression of genes and develop pharmacological strategies to revert these TRIB2-mediated changes, thereby overcoming therapy resistance.

Harmine and Piperlongumine Revert TRIB2-Mediated Drug Resistance

Poor survival and treatment failure of patients with cancer are mainly due to therapy resistance. Tribbles homologue 2 (TRIB2) has recently been identified as a protein that promotes resistance to several anti-cancer drugs. In this study, RNA sequencing and bioinformatics analysis were used to characterise the impact of TRIB2 on the expression of genes and develop pharmacological strategies to revert these TRIB2-mediated changes, thereby overcoming therapy resistance.

Multiple Myeloma: Available Therapies and Causes of Drug Resistance

Multiple myeloma is a rare debilitating hematologic malignancy of plasma cells, a type of immune cell responsible for producing antibodies. Abnormal accumulation of myeloma plasma cells within the bone marrow will result in the disruption of haematopoiesis (anaemia, infections), increased bone turnover (osteolytic lesions, hypercalcemia) and excessive amounts of monoclonal immunoglobular proteins (kidney failure). Even though multiple myeloma is treatable for a while, it still remains as an incurable disease with a severe impact in the patients’ quality of life.

Mieloma múltiplo: terapias disponíveis e causas de resistência a medicamentos

O mieloma múltiplo é uma neoplasia hematológica debilitante das células plasmáticas, um tipo de célula imune responsável pela produção de anticorpos. A proliferação anómala de células plasmáticas do mieloma na medula óssea resultará na interrupção da hematopoiese (anemia, infeções), aumento da renovação óssea (lesões osteolíticas, hipercalcemia) e produção excessiva de imunoglobulinas monoclonais (insuficiência renal). Embora o mieloma múltiplo seja tratável do ponto de vista clínico, ainda permanece como uma doença incurável, com um forte impacto na qualidade de vida dos doentes.

The influence of tumor metabolism on tumor progression and drug resistance


Diana Tavares-Valente1,2; Sara Granja1; Fátima Baltazar1; Odília Queirós2

1 Life and Health Sciences Research Institute (ICVS)/ School of Medicine/ University of Minho, Campus de Gualtar, Braga, 4710-057, Portugal;

Budapest Cancer Think Tank

Research Centre for Natural Sciences of the Hungarian Academy of Sciences, Budapest, Hungary

 

26 - 27 March, 2017

 

See more informations here: http://gyer1-6.sote.hu/bctt/

Budapest Cancer Think Tank

Research Centre for Natural Sciences of the Hungarian Academy of Sciences, Budapest, Hungary

 

26 - 27 March, 2017

 

See more informations here: http://gyer1-6.sote.hu/bctt/